ERBB2 and cancer: Ogitani et al. demonstrated that T-DXd exhibited a great potential to inhibit the growth of low HER2-expressing and trastuzumab- or trastuzumab emtansine (T-DM1)-insensitive HER2-positive cancer cells in patient-derived xenograft models1,3.